Introduction
Kidney transplantation is associated with improved survival, better quality of life and reduced costs when compared to long-term dialysis in ESRD patients [1] . Unfortunately, the demand far exceeds the available kidneys for cadaveric transplantation. Based on Malaysian registry, there are 7597 new dialysis patients and only 104 new transplant patients by the end of 2015 [2] . Therefore, due to the limited number of cadaveric, as well as living related renal transplant (LRRT) in our country, there is a need to explore transplant with ABO-incompatible and positive for anti-Human Leukocyte Antigen (HLA) donor-specific antibodies (DSA).
Patients become sensitized after exposure to HLA from blood transfusions, previous transplantation or pregnancy. Sensitized patients are prone to a drastic rise in risk of hyper-acute rejection and allograft loss. In order to minimize the risk, various desensitization protocols have been adopted by different centers and the outcomes vary one from another. Desensitization protocols began to emerge in the late 1990's. The first series published by Montgomery et.al, has established a successful protocol using low-dose intravenous immunoglobulin (IVIG) (100 mg/kg) with plasma exchange (PLEX) to remove donor specific antibodies (DSA). In their cohort, four out of seven patients have positive crossmatch (flow cytometry or cytotoxic) prior to the kidney transplantation [3, 4] Center, uses high-dose IVIG (2 g/kg) in multiple doses in both living donor positive crossmatch recipients and HLA-sensitized candidates on the deceased donor waiting list [5, 6] . Apart from high dose IVIG, the latter group has also implemented a protocol that involves both IVIG and rituximab [7] .
Despite better understanding on the development of the HLA antibody and advancements in immunosuppressive therapy, transplantation in sensitized patients remains challenging. In this case-series, we describe our limited experience of LRRT in sensitized patients.
Methods
We recruited all sensitized kidney transplant patients (positive DSA), who were transplanted at UMMC from February 2016 until April 2017. Those patients showing negative for DSA and ABO-incompatible transplant were excluded. The DSA and final white blood cell crossmatch (Complement-dependent cytotoxic [CDC]) were sent 1 month prior to the kidney transplant. Following positive DSA, the recipient will need further test for flow cytometry (FC). Patients and donors baseline characteristic, blood groups and immunological profile were documented. Following this, there will be a follow-up of all patients as per our standard clinical practice immediately post-transplant and these patients will be subsequently monitored with repeat DSA tests and protocol biopsy at 1-month, 3-month, 6-month and yearly, post-transplant. Patient's progress and outcome are documented. Primary outcome were to look at the incidence of delayed graft function (dialysis during first week of transplantation), graft function at 1, 3, 6 and 12 months post-transplant and incidence of acute rejection (borderline, cellular and antibody mediated rejection [ABMR]).
Results
During this study period, a total of five patients were recruited (Table 1 ). Our first patient developed a sudden onset of right hypochondrium pain, acute hepatitis and his creatinine remained static, around 200 mmol/L on D+4. He was initially given an intravenous Basiliximab as induction agent and his DSAs were back after kidney transplantation. In view of his condition and positive DSAs, we have empirically treated him with plasma exchange and IVIG. The second patient suffered a sudden onset of shortness of breath, hemoptysis and drop in hemoglobin on D+4 post-transplant. Even though she was given IVI rituximab and thymoglobulin, her general conditions only improved after few sessions of plasma exchange. There were no other obvious causes of their deterioration. We presume that both patients had ABMR as a result of preformed DSA.
Following our initial experience, we have adopted a protocol consisting of IVI Rituximab at D-14 (14 days before transplantation), IVI Methylprednisolone 500 mg for 2 doses (D0 -on the day of transplantation), IVI Thymoglobulin D0 until D+4 (total of 5 mg/kg), plasma exchanges for 2 cycles post-transplant (for DSA positive, flow cytometry negative and mean fluorescence index (MFI) < 3000) with a maintenance of tacrolimus, MPA and prednisolone. For patients with positive DSA and MFI ≥ 3000 or positive flow cytometry, extra cycles of plasma exchanges needed prior to the transplant as part of desensitization protocol. All subsequent three patients did well and achieved immediate graft function. Serum creatinine was stable at 1-month, 3month, 6-month and at 9-month for all the patients (Fig. 1 ). Three patients had borderline changes on protocol biopsy but none of them had acute rejection (Table 2 ). There were no episodes of pulse methylprednisolone since their creatinine remained stable. At 3 months, their DSA level was negative except for patient 1 and 4. For patient 1, we were unable to repeat his subsequent DSA because of financial reasons and his renal functions remain stable at 110 umol/L. Meanwhile, for patient 4, DSA for B58 was negative and the MFI for Cw1 were reducing in trend. Her serum creatinine is now stable at 120 umol/L. None of the patients developed any other de-novo DSA.
Discussion
Kidney transplant has been shown to be superior to other modes of renal replacement therapy even though in sensitized patients. Vo AA et.al, has examined the outcomes of high-dose IVIG and rituximab in 146 sensitized patients (living and deceased donors). They found that at 48-months, patients and graft survival was 95% and 87.5%, respectively [7] . These survival outcomes were better when compared to patients who remained on dialysis during the study period. However, this group of sensitized patients needs special desensitization protocol in order to reduce the risk of rejection and graft loss. Based on our limited experience, we have adopted a protocol consisting of low-dose intravenous rituximab, intravenous thymoglobulin and plasma exchange as an induction/desensitization therapy. Following this, the patient will be put on MPA, Tacrolimus and Prednisolone as part of maintenance therapy. From the minimum of 9-months follow-up all the patients have stable graft function, negative DSA after 3-months and 6-months post-transplant, except for patient 1 who we are unable to repeat his DSA and patient 4 who showed reduction in her DSA. This has been proven by David Shaffer et al. in their 3-years prospective study that desensitization with IVIG and rituximab results in early and sustained DSA removal and low incidence of acute rejection [8] .
We have yet to follow-up on all these patients to look at their graft function and any incidence of acute rejection at 12-months and subsequently their longer-term outcome.
Apart from desensitization protocol, close monitoring post-transplantation is extremely important; thus, we advocate for protocol biopsy especially during the first year. This protocol biopsy should be interpreted together with serum creatinine and the presence of DSAs.
Conclusion
Transplant in sensitized patients is possible and may provide a significant survival benefit as opposed to waiting for a compatible organ and on dialysis. However, early preparation and planning are both important for this to work. Desensitization protocols may also help to overcome incompatibility barriers in live-donor renal transplantation. Apart from close creatinine and drug levels monitoring, DSA monitoring and protocol biopsy is another valuable tool to detect early rejection. 
